Business
Aurora Spine Corporation Announces Record Fourth Quarter and FY25 Financial Results
– Q4 revenue surpasses $5 million threshold –  –Company to host confe...
About this update from Aurora Spine Corp.
[{"type":"text","content":"Aurora Spine Corporation Announces Record Fourth Quarter and FY25 Financial Results\n– Q4 revenue surpasses $5 million threshold – –Company to host conference call today, April 30th  at 11am ET/8am PT – NOT FOR DISTRIBUTION IN THE UNITED STATES OR OVER UNITED STATES WIRE SERVICES CARLSBAD, Calif., April 30, 2026 (GLOBE NEWSWIRE) -- Aurora Spine Corporation (“Aurora Spine” or the “Company”) (TSXV: ASG) (OTCQB: ASAPF), a leader in the development of groundbreaking medical devices for spinal surgery, today announced its financial results for the fourth quarter and fiscal year ended December 31, 2025. All figures are in U.S. dollars. Financial and Business Highlights First $5 million quarter – Q4 2025 sales were $5,022,865 compared to $4,430,755 in Q3 2025 and $4,702,317 in Q4 2024. Strong improvements in EBITDAC – EBITDAC for FY2025 was $587,532 compared to $282,450 in 2024, an improvement of 108% or $305,082. EBITDAC for Q4 was $301,112 compared to $(320,360), an improvement of $621,472. Increased gross profit margin – Gross profit margin on total revenues was 62.4% for Q4 of 2025, compared to 57.8% in Q4 of 2024 and increased year over year to 61.0% in 2025 from 60.5% in 2024, due to improved product mix, lower implant costs and royalty expenses. Product growth – Sales of the SI joint implants increased in aggregate by $0.7 million in 2025 compared to 2024, an 8.4% increase. In Q4 2025, Zip sales increased by $0.35 million to $1.8 million, a 23% increase compared to Q4 2024.  Biologics – Successfully launched Aurora Biologics in late 2025 which contributed to a $0.2 million increase in biologic sales for 2025, a 34% increase over 2024 with the majority of growth coming in 2H 2025. The Company endeavors to sell biologics with all its implants. Training – The Company continued to conduct more advanced training sessions and cadaver labs that introduced leading orthopedic, neurosurgical, and pain management physicians to the ZIP™ and SiLO™ implants. Management Commentary \"I am very pleased with the company’s performance during 2025, which built momentum throughout the year and especially into the fourth quarter, where we reported record revenues in excess of $5 million,” said Trent Northcu...